Cellectis is a biopharmaceutical company with a single goal: to develop adoptive immunotherapies for cancer.
In order to address unmet medical needs, Cellectis is developing immunotherapies based on CAR T-cells. The specificity of those allogeneic therapies is that T-cells from healthy donors are genetically edited with our proprietary technology TALEN®, to seek and destroy cancer cells. This approach could lead to a drug that would be cost-effective, easily distributed across all geographies and available to patients who don’t have enough T-cells to undergo an autologous CAR-T therapy (based on the patient’s own T-cells).
T-cells, which are cells from the immune system, can be engineered to express a Chimeric Antigen Receptor or CAR, a molecule that enables them to recognize specific antigens that are present on the surface of cancer cells. By targeting a protein expressed by tumoral cells, the CAR leads the immune system towards cancer, which is recognized as harmful. The immune system is then able to attack cancer cells.